{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T08:23:21Z","timestamp":1775723001069,"version":"3.50.1"},"reference-count":122,"publisher":"Portland Press Ltd.","issue":"4","content-domain":{"domain":["portlandpress.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,8,30]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Inflammation has been highlighted as a key factor in pulmonary arterial hypertension (PAH) development, particularly interleukin-6 (IL-6). IL-6 activates JAK-STAT signalling to induce transcription of pro-inflammatory and pro-angiogenic genes, enabling PAH progression, as well as the transcription of suppressor of cytokine signalling 3 (SOCS3) which limits IL-6 signalling. Current PAH therapies include prostanoid drugs which induce vasodilation via stimulating intracellular 3\u2032,5\u2032-cyclic adenosine monophosphate (cAMP) levels. cAMP can also inhibit IL-6-mediated endothelial dysfunction via the induction of SOCS3. Thus, we propose that an important mechanism by which cAMP-mobilising prostanoid drugs limit PAH is by inhibiting IL-6-mediated pulmonary inflammation and remodelling via SOCS3 inhibition of IL-6 signalling. Further clarification may result in effective strategies with which to target the IL-6\/JAK-STAT signalling pathway in PAH.<\/jats:p>","DOI":"10.1042\/bst20190046","type":"journal-article","created":{"date-parts":[[2019,7,24]],"date-time":"2019-07-24T14:26:16Z","timestamp":1563978376000},"page":"1143-1156","update-policy":"https:\/\/doi.org\/10.1042\/crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Is there a role for prostanoid-mediated inhibition of IL-6<i>trans<\/i>-signalling in the management of pulmonary arterial hypertension?"],"prefix":"10.1042","volume":"47","author":[{"given":"Gillian A.","family":"Durham","sequence":"first","affiliation":[{"name":"Pharmacology and Experimental Therapeutics Research Group, School of Pharmacy and Medical Sciences, University of Bradford, Bradford BD7 1DP, U.K."},{"name":"Centre for Atherothrombosis and Metabolic Disease, Hull York Medical School, University of Hull, Hull HU6 7RX, U.K."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9803-7164","authenticated-orcid":false,"given":"Timothy M.","family":"Palmer","sequence":"additional","affiliation":[{"name":"Centre for Atherothrombosis and Metabolic Disease, Hull York Medical School, University of Hull, Hull HU6 7RX, U.K."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"288","published-online":{"date-parts":[[2019,7,24]]},"reference":[{"key":"2021111915542046700_BST-2019-0046CC1","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1164\/rccm.201203-0383OC","article-title":"Changing demographics, epidemiology, and survival of incident pulmonary arterial hypertension: results from the pulmonary hypertension registry of the United Kingdom and Ireland","volume":"186","year":"2012","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"2021111915542046700_BST-2019-0046CC2","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1161\/CIRCRESAHA.115.301146","article-title":"Pulmonary arterial hypertension: the clinical syndrome","volume":"115","year":"2014","journal-title":"Circ. Res."},{"key":"2021111915542046700_BST-2019-0046CC3","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1378\/chest.11-1460","article-title":"An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry","volume":"142","year":"2012","journal-title":"Chest"},{"key":"2021111915542046700_BST-2019-0046CC4","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/j.healun.2017.02.016","article-title":"The Giessen Pulmonary Hypertension Registry: survival in pulmonary hypertension subgroups","volume":"36","year":"2017","journal-title":"J. Heart Lung Transplant."},{"key":"2021111915542046700_BST-2019-0046CC5","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/j.ijcard.2012.10.026","article-title":"Elderly patients diagnosed with idiopathic pulmonary arterial hypertension: results from the COMPERA registry","volume":"168","year":"2013","journal-title":"Int. J. Cardiol."},{"key":"2021111915542046700_BST-2019-0046CC6","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1016\/j.amjcard.2017.01.015","article-title":"Survival of Japanese patients with idiopathic\/heritable pulmonary arterial hypertension","volume":"119","year":"2017","journal-title":"Am. J. Cardiol."},{"key":"2021111915542046700_BST-2019-0046CC7","doi-asserted-by":"publisher","first-page":"11","DOI":"10.11909\/j.issn.1671-5411.2017.01.001","article-title":"Epidemiology of pulmonary hypertension in the elderly","volume":"14","year":"2017","journal-title":"J. Geriatr. Cardiol."},{"key":"2021111915542046700_BST-2019-0046CC8","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1016\/S0735-1097(02)02012-0","article-title":"Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival","volume":"40","year":"2002","journal-title":"J. Am. Coll. Cardiol."},{"key":"2021111915542046700_BST-2019-0046CC9","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/1465-9921-15-47","article-title":"Inflammatory cytokines in pulmonary hypertension","volume":"15","year":"2014","journal-title":"Respir. Res."},{"key":"2021111915542046700_BST-2019-0046CC10","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1161\/CIRCULATIONAHA.109.933762","article-title":"Elevated levels of inflammatory cytokines predict survival in idiopathic and familial pulmonary arterial hypertension","volume":"122","year":"2010","journal-title":"Circulation"},{"key":"2021111915542046700_BST-2019-0046CC11","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.jash.2017.01.011","article-title":"Interleukin-6 -572C\/G polymorphism is associated with serum interleukin-6 levels and risk of idiopathic pulmonary arterial hypertension","volume":"11","year":"2017","journal-title":"J. Am. Soc. Hypertens."},{"key":"2021111915542046700_BST-2019-0046CC12","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.cyto.2015.06.018","article-title":"Enhanced IL-6 trans-signaling in pulmonary arterial hypertension and its potential role in disease-related systemic damage","volume":"76","year":"2015","journal-title":"Cytokine"},{"key":"2021111915542046700_BST-2019-0046CC13","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s12964-018-0268-4","article-title":"Activation of the JAK\/STAT3 and PI3K\/AKT pathways are crucial for IL-6 trans-signaling-mediated pro-inflammatory response in human vascular endothelial cells","volume":"16","year":"2018","journal-title":"Cell Commun. Signal."},{"key":"2021111915542046700_BST-2019-0046CC14","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.3892\/or.2016.4544","article-title":"IL-6 mediates the signal pathway of JAK-STAT3-VEGF-C promoting growth, invasion and lymphangiogenesis in gastric cancer","volume":"35","year":"2016","journal-title":"Oncol. Rep."},{"key":"2021111915542046700_BST-2019-0046CC15","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1681\/ASN.2015101169","article-title":"IL-6 trans-signaling links inflammation with angiogenesis in the peritoneal membrane","volume":"28","year":"2017","journal-title":"J. Am. Soc. Nephrol."},{"key":"2021111915542046700_BST-2019-0046CC16","doi-asserted-by":"publisher","first-page":"6843","DOI":"10.1074\/jbc.M710342200","article-title":"Identification of CCAAT\/enhancer-binding proteins as exchange protein activated by cAMP-activated transcription factors that mediate the induction of the SOCS-3 gene","volume":"283","year":"2008","journal-title":"J. Biol. Chem."},{"key":"2021111915542046700_BST-2019-0046CC17","doi-asserted-by":"publisher","first-page":"17391","DOI":"10.1074\/jbc.M109.015370","article-title":"Activation of protein kinase C\u03b1 by EPAC1 is required for the ERK- and CCAAT\/enhancer-binding protein \u03b2-dependent induction of the SOCS-3 gene by cyclic AMP in COS1 cells","volume":"284","year":"2009","journal-title":"J. Biol. Chem."},{"key":"2021111915542046700_BST-2019-0046CC18","doi-asserted-by":"publisher","first-page":"6333","DOI":"10.1128\/MCB.00207-06","article-title":"Exchange protein activated by cyclic AMP (Epac)-mediated induction of suppressor of cytokine signaling 3 (SOCS-3) in vascular endothelial cells","volume":"26","year":"2006","journal-title":"Mol. Cell. Biol."},{"key":"2021111915542046700_BST-2019-0046CC19","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.ajpath.2011.03.040","article-title":"Plexiform lesions in pulmonary arterial hypertension composition, architecture, and microenvironment","volume":"179","year":"2011","journal-title":"Am. J. Pathol."},{"key":"2021111915542046700_BST-2019-0046CC20","first-page":"275","article-title":"Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension","volume":"144","year":"1994","journal-title":"Am. J. Pathol."},{"key":"2021111915542046700_BST-2019-0046CC21","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1002\/path.953","article-title":"Expression of angiogenesis-related molecules in plexiform lesions in severe pulmonary hypertension: evidence for a process of disordered angiogenesis","volume":"195","year":"2001","journal-title":"J. Pathol."},{"key":"2021111915542046700_BST-2019-0046CC22","doi-asserted-by":"publisher","first-page":"2045893217752912","DOI":"10.1177\/2045893217752912","article-title":"Endothelial dysfunction in pulmonary arterial hypertension: an evolving landscape (2017 Grover Conference Series)","volume":"8","year":"2018","journal-title":"Pulm. Circ."},{"key":"2021111915542046700_BST-2019-0046CC23","doi-asserted-by":"publisher","first-page":"2045894018798569","DOI":"10.1177\/2045894018798569","article-title":"The role of endothelial leak in pulmonary hypertension (2017 Grover Conference Series)","volume":"8","year":"2018","journal-title":"Pulm. Circ."},{"key":"2021111915542046700_BST-2019-0046CC24","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1164\/rccm.201408-1509OC","article-title":"Bone morphogenetic protein receptor type II deficiency and increased inflammatory cytokine production. A gateway to pulmonary arterial hypertension","volume":"192","year":"2015","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"2021111915542046700_BST-2019-0046CC25","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1038\/nm.3877","article-title":"Selective enhancement of endothelial BMPR-II with BMP9 reverses pulmonary arterial hypertension","volume":"21","year":"2015","journal-title":"Nat. Med."},{"key":"2021111915542046700_BST-2019-0046CC26","doi-asserted-by":"publisher","first-page":"PA1820","DOI":"10.1183\/13993003.congress-2016.PA1820","article-title":"Over expression of endothelin-1 (ET-1) in lung fibroblasts (LFb) from patients with pulmonary arterial hypertension (PAH), evidence for loss of inhibitory control","volume":"48","year":"2016","journal-title":"Eur. Respir. J."},{"key":"2021111915542046700_BST-2019-0046CC27","doi-asserted-by":"publisher","first-page":"14","DOI":"10.21542\/gcsp.2017.14","article-title":"Nitric oxide and pulmonary arterial hypertension","volume":"2017","year":"2017","journal-title":"Glob. Cardiol. Sci. Pract."},{"key":"2021111915542046700_BST-2019-0046CC28","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1080\/17476348.2017.1317599","article-title":"The prostacyclin pathway in pulmonary arterial hypertension: a clinical review","volume":"11","year":"2017","journal-title":"Exp. Rev. Respir. Med."},{"key":"2021111915542046700_BST-2019-0046CC29","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1183\/13993003.01448-2015","article-title":"Role of interleukin-1 receptor 1\/MyD88 signalling in the development and progression of pulmonary hypertension","volume":"48","year":"2016","journal-title":"Eur. Respir. J."},{"key":"2021111915542046700_BST-2019-0046CC30","doi-asserted-by":"publisher","first-page":"159","DOI":"10.14503\/THIJ-12-3012","article-title":"Serum levels of soluble ICAM-1 in children with pulmonary artery hypertension","volume":"41","year":"2014","journal-title":"Tex. Heart Inst. J."},{"key":"2021111915542046700_BST-2019-0046CC31","doi-asserted-by":"publisher","first-page":"2467","DOI":"10.1016\/j.cellsig.2015.09.003","article-title":"VCAM-1 is a TGF-\u03b21 inducible gene upregulated in idiopathic pulmonary fibrosis","volume":"27","year":"2015","journal-title":"Cell. Signal."},{"key":"2021111915542046700_BST-2019-0046CC32","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1093\/abbs\/gmx095","article-title":"Immune cells and autoantibodies in pulmonary arterial hypertension","volume":"49","year":"2017","journal-title":"Acta Biochim. Biophys. Sin."},{"key":"2021111915542046700_BST-2019-0046CC33","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/1465-9921-10-6","article-title":"Impact of interleukin-6 on hypoxia-induced pulmonary hypertension and lung inflammation in mice","volume":"10","year":"2009","journal-title":"Respir. Res."},{"key":"2021111915542046700_BST-2019-0046CC34","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1161\/CIRCRESAHA.108.182014","article-title":"Interleukin-6 overexpression induces pulmonary hypertension","volume":"104","year":"2009","journal-title":"Circ. Res."},{"key":"2021111915542046700_BST-2019-0046CC35","doi-asserted-by":"publisher","first-page":"2045894018780734","DOI":"10.1177\/2045894018780734","article-title":"Interleukin-6 trans-signaling contributes to chronic hypoxia-induced pulmonary hypertension","volume":"8","year":"2018","journal-title":"Pulm. Circ."},{"key":"2021111915542046700_BST-2019-0046CC36","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1126\/science.8511589","article-title":"IL-6-induced homodimerization of gp130 and associated activation of a tyrosine kinase","volume":"260","year":"1993","journal-title":"Science"},{"key":"2021111915542046700_BST-2019-0046CC37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1042\/BJ20140712","article-title":"The molecular regulation of Janus kinase (JAK) activation","volume":"462","year":"2014","journal-title":"Biochem. J."},{"key":"2021111915542046700_BST-2019-0046CC38","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1002\/j.1460-2075.1995.tb07128.x","article-title":"A major role for the protein tyrosine kinase JAK1 in the JAK\/STAT signal transduction pathway in response to interleukin-6","volume":"14","year":"1995","journal-title":"EMBO J."},{"key":"2021111915542046700_BST-2019-0046CC39","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1038\/nsmb.2849","article-title":"Molecular basis for pseudokinase-dependent autoinhibition of JAK2 tyrosine kinase","volume":"21","year":"2014","journal-title":"Nat. Struct. Mol. Biol."},{"key":"2021111915542046700_BST-2019-0046CC40","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1038\/nsmb.2673","article-title":"Structure of a pseudokinase-domain switch that controls oncogenic activation of Jak kinases","volume":"20","year":"2013","journal-title":"Nat. Struct. Mol. Biol."},{"key":"2021111915542046700_BST-2019-0046CC41","doi-asserted-by":"publisher","first-page":"1249783","DOI":"10.1126\/science.1249783","article-title":"Mechanism of activation of protein kinase JAK2 by the growth hormone receptor","volume":"344","year":"2014","journal-title":"Science"},{"key":"2021111915542046700_BST-2019-0046CC42","doi-asserted-by":"publisher","first-page":"12999","DOI":"10.1074\/jbc.271.22.12999","article-title":"Differential activation of acute phase response factor\/Stat3 and Stat1 via the cytoplasmic domain of the interleukin 6 signal transducer gp130. II. Src homology SH2 domains define the specificity of stat factor activation","volume":"271","year":"1996","journal-title":"J. Biol. Chem."},{"key":"2021111915542046700_BST-2019-0046CC43","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1126\/science.7871433","article-title":"Choice of STATs and other substrates specified by modular tyrosine-based motifs in cytokine receptors","volume":"267","year":"1995","journal-title":"Science"},{"key":"2021111915542046700_BST-2019-0046CC44","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1006\/bbrc.1998.8829","article-title":"STAT3 forms stable homodimers in the presence of divalent cations prior to activation","volume":"247","year":"1998","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"2021111915542046700_BST-2019-0046CC45","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/0092-8674(94)90357-3","article-title":"Interferon activation of the transcription factor Stat91 involves dimerization through SH2-phosphotyrosyl peptide interactions","volume":"76","year":"1994","journal-title":"Cell"},{"key":"2021111915542046700_BST-2019-0046CC46","doi-asserted-by":"publisher","first-page":"2913","DOI":"10.1128\/MCB.19.4.2913","article-title":"Design of conditionally active STATs: insights into STAT activation and gene regulatory function","volume":"19","year":"1999","journal-title":"Mol. Cell. Biol."},{"key":"2021111915542046700_BST-2019-0046CC47","doi-asserted-by":"publisher","first-page":"2852","DOI":"10.1182\/blood-2009-10-230060","article-title":"STAT3 is constitutively phosphorylated on serine 727 residues, binds DNA, and activates transcription in CLL cells","volume":"115","year":"2010","journal-title":"Blood"},{"key":"2021111915542046700_BST-2019-0046CC48","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1038\/sj.onc.1206226","article-title":"Interleukin-6 promotes cervical tumor growth by VEGF-dependent angiogenesis via a STAT3 pathway","volume":"22","year":"2003","journal-title":"Oncogene"},{"key":"2021111915542046700_BST-2019-0046CC49","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/nature14228","article-title":"A gp130-Src-YAP module links inflammation to epithelial regeneration","volume":"519","year":"2015","journal-title":"Nature"},{"key":"2021111915542046700_BST-2019-0046CC50","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1128\/MCB.18.3.1525","article-title":"Protein tyrosine phosphatase 2 (SHP-2) moderates signaling by gp130 but is not required for the induction of acute-phase plasma protein genes in hepatic cells","volume":"18","year":"1998","journal-title":"Mol. Cell. Biol."},{"key":"2021111915542046700_BST-2019-0046CC51","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.cytogfr.2015.07.004","article-title":"Interleukin-6: biology, signaling and strategies of blockade","volume":"26","year":"2015","journal-title":"Cytokine Growth Factor Rev."},{"key":"2021111915542046700_BST-2019-0046CC52","doi-asserted-by":"publisher","first-page":"L187","DOI":"10.1152\/ajplung.00303.2015","article-title":"Raf\/ERK drives the proliferative and invasive phenotype of BMPR2-silenced pulmonary artery endothelial cells","volume":"310","year":"2016","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"2021111915542046700_BST-2019-0046CC53","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1093\/hmg\/11.13.1517","article-title":"Functional analysis of bone morphogenetic protein type II receptor mutations underlying primary pulmonary hypertension","volume":"11","year":"2002","journal-title":"Hum. Mol. Genet."},{"key":"2021111915542046700_BST-2019-0046CC54","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1089\/dna.2016.3342","article-title":"Suppression of phosphatidylinositol 3-kinase\/Akt signaling attenuates hypoxia-induced pulmonary hypertension through the downregulation of lysyl oxidase","volume":"35","year":"2016","journal-title":"DNA Cell Biol."},{"key":"2021111915542046700_BST-2019-0046CC55","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1016\/j.celrep.2015.09.049","article-title":"Matrix remodeling promotes pulmonary hypertension through feedback mechanoactivation of the YAP\/TAZ-miR-130\/301 circuit","volume":"13","year":"2015","journal-title":"Cell Rep."},{"key":"2021111915542046700_BST-2019-0046CC56","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1091\/mbc.5.7.819","article-title":"Phosphorylation and internalization of gp130 occur after IL-6 activation of Jak2 kinase in hepatocytes","volume":"5","year":"1994","journal-title":"Mol. Biol. Cell"},{"key":"2021111915542046700_BST-2019-0046CC57","doi-asserted-by":"crossref","first-page":"2900","DOI":"10.4049\/jimmunol.143.9.2900","article-title":"Characterization of IL-6 receptor expression by monoclonal and polyclonal antibodies","volume":"143","year":"1989","journal-title":"J. Immunol."},{"key":"2021111915542046700_BST-2019-0046CC58","first-page":"1508","article-title":"Characterization and functional studies on rat liver fat-storing cell line and freshly isolated hepatocyte coculture system","volume":"146","year":"1995","journal-title":"Am. J. Pathol."},{"key":"2021111915542046700_BST-2019-0046CC59","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1002\/eji.1830230226","article-title":"The soluble interleukin-6 receptor is generated by shedding","volume":"23","year":"1993","journal-title":"Eur. J. Immunol."},{"key":"2021111915542046700_BST-2019-0046CC60","doi-asserted-by":"publisher","first-page":"25550","DOI":"10.1038\/srep25550","article-title":"Cleavage site localization differentially controls interleukin-6 receptor proteolysis by ADAM10 and ADAM17","volume":"6","year":"2016","journal-title":"Sci. Rep."},{"key":"2021111915542046700_BST-2019-0046CC61","doi-asserted-by":"publisher","first-page":"26059","DOI":"10.1074\/jbc.M115.649509","article-title":"Shedding of endogenous interleukin-6 receptor (IL-6R) is governed by a disintegrin and metalloproteinase (ADAM) proteases while a full-length IL-6R isoform localizes to circulating microvesicles","volume":"290","year":"2015","journal-title":"J. Biol. Chem."},{"key":"2021111915542046700_BST-2019-0046CC62","doi-asserted-by":"publisher","first-page":"44053","DOI":"10.1038\/srep44053","article-title":"Meprin metalloproteases generate biologically active soluble interleukin-6 receptor to induce trans-signaling","volume":"7","year":"2017","journal-title":"Sci. Rep."},{"key":"2021111915542046700_BST-2019-0046CC63","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0165-2478(99)00040-1","article-title":"Generation of \u2018truncated\u2019 interleukin-6 receptor (IL-6R) mRNA by alternative splicing; a possible source of soluble IL-6R","volume":"68","year":"1999","journal-title":"Immunol. Lett."},{"key":"2021111915542046700_BST-2019-0046CC64","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/1043-4666(92)90043-Q","article-title":"Isolation of an mRNA encoding a soluble form of the human interleukin-6 receptor","volume":"4","year":"1992","journal-title":"Cytokine"},{"key":"2021111915542046700_BST-2019-0046CC65","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.7150\/ijbs.4989","article-title":"IL-6 trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6","volume":"8","year":"2012","journal-title":"Int. J. Biol. Sci."},{"key":"2021111915542046700_BST-2019-0046CC66","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.1172\/JCI96462","article-title":"Ectopic upregulation of membrane-bound IL6R drives vascular remodeling in pulmonary arterial hypertension","volume":"128","year":"2018","journal-title":"J. Clin. Invest."},{"key":"2021111915542046700_BST-2019-0046CC67","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1046\/j.1432-1327.2001.01867.x","article-title":"Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses","volume":"268","year":"2001","journal-title":"Eur. J. Biochem."},{"key":"2021111915542046700_BST-2019-0046CC68","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/S0014-5793(97)00750-3","article-title":"Cloning and expression of an alternatively spliced mRNA encoding a soluble form of the human interleukin-6 signal transducer gp130","volume":"412","year":"1997","journal-title":"FEBS Lett."},{"key":"2021111915542046700_BST-2019-0046CC69","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1182\/blood.V82.4.1120.1120","article-title":"Soluble forms of the interleukin-6 signal-transducing receptor component gp130 in human serum possessing a potential to inhibit signals through membrane-anchored gp130","volume":"82","year":"1993","journal-title":"Blood"},{"key":"2021111915542046700_BST-2019-0046CC70","first-page":"269","article-title":"Brain natriuretic peptide in pulmonary arterial hypertension: biomarker and potential therapeutic agent","volume":"3","year":"2009","journal-title":"Drug Des. Devel. Ther."},{"key":"2021111915542046700_BST-2019-0046CC71","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1513\/AnnalsATS.201410-463OC","article-title":"Interleukin-6 and tumor necrosis factor-\u03b1 are associated with quality of life-related symptoms in pulmonary arterial hypertension","volume":"12","year":"2015","journal-title":"Ann. Am. Thorac. Soc."},{"key":"2021111915542046700_BST-2019-0046CC72","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/j.healun.2017.08.011","article-title":"Interleukin-6 is independently associated with right ventricular function in pulmonary arterial hypertension","volume":"37","year":"2018","journal-title":"J. Heart Lung Transplant."},{"key":"2021111915542046700_BST-2019-0046CC73","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.phrs.2017.08.003","article-title":"Animal models of pulmonary arterial hypertension: a systematic review and meta-analysis of data from 6126 animals","volume":"125","year":"2017","journal-title":"Pharmacol. Res."},{"key":"2021111915542046700_BST-2019-0046CC74","doi-asserted-by":"publisher","first-page":"L238","DOI":"10.1152\/ajplung.90591.2008","article-title":"Sustained hypoxia promotes the development of a pulmonary artery-specific chronic inflammatory microenvironment","volume":"297","year":"2009","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"2021111915542046700_BST-2019-0046CC75","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1161\/01.RES.0000243584.45145.3f","article-title":"Hypoxia-induced pulmonary vascular remodeling: cellular and molecular mechanisms","volume":"99","year":"2006","journal-title":"Circ. Res."},{"key":"2021111915542046700_BST-2019-0046CC76","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1086\/678508","article-title":"The Sugen 5416\/hypoxia mouse model of pulmonary hypertension revisited: long-term follow-up","volume":"4","year":"2014","journal-title":"Pulm. Circ."},{"key":"2021111915542046700_BST-2019-0046CC77","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1113\/JP275864","article-title":"Crosstalk proposal: the mouse SuHx model is a good model of pulmonary arterial hypertension","volume":"597","year":"2019","journal-title":"J. Physiol."},{"key":"2021111915542046700_BST-2019-0046CC78","doi-asserted-by":"publisher","first-page":"434","DOI":"10.4103\/2045-8932.105031","article-title":"New models of pulmonary hypertension based on VEGF receptor blockade-induced endothelial cell apoptosis","volume":"2","year":"2012","journal-title":"Pulm. Circ."},{"key":"2021111915542046700_BST-2019-0046CC79","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1165\/rcmb.2012-0077OC","article-title":"Severe pulmonary arterial hypertension induced by SU5416 and ovalbumin immunization","volume":"47","year":"2012","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"2021111915542046700_BST-2019-0046CC80","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.pupt.2015.09.007","article-title":"Exploring the monocrotaline animal model for the study of pulmonary arterial hypertension: a network approach","volume":"35","year":"2015","journal-title":"Pulm. Pharmacol. Ther."},{"key":"2021111915542046700_BST-2019-0046CC81","doi-asserted-by":"publisher","first-page":"H149","DOI":"10.1152\/ajpheart.1981.240.2.H149","article-title":"Changes in pulmonary structure and function induced by monocrotaline intoxication","volume":"240","year":"1981","journal-title":"Am. J. Physiol."},{"key":"2021111915542046700_BST-2019-0046CC82","doi-asserted-by":"publisher","first-page":"L363","DOI":"10.1152\/ajplung.00212.2011","article-title":"The monocrotaline model of pulmonary hypertension in perspective","volume":"302","year":"2012","journal-title":"Am. J. Physiol Lung Cell. Mol. Physiol."},{"key":"2021111915542046700_BST-2019-0046CC83","doi-asserted-by":"publisher","first-page":"E2677","DOI":"10.1073\/pnas.1424774112","article-title":"Interleukin-6\/interleukin-21 signaling axis is critical in the pathogenesis of pulmonary arterial hypertension","volume":"112","year":"2015","journal-title":"Proc. Natl Acad. Sci. U.S.A."},{"key":"2021111915542046700_BST-2019-0046CC84","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1158\/1535-7163.MCT-12-1082","article-title":"Discovery of a novel orally active small-molecule gp130 inhibitor for the treatment of ovarian cancer","volume":"12","year":"2013","journal-title":"Mol. Cancer Ther."},{"key":"2021111915542046700_BST-2019-0046CC85","doi-asserted-by":"publisher","first-page":"1356.e1","DOI":"10.1016\/j.cjca.2016.02.058","article-title":"Glycoprotein 130 inhibitor ameliorates monocrotaline-induced pulmonary hypertension in rats","volume":"32","year":"2016","journal-title":"Can. J. Cardiol."},{"key":"2021111915542046700_BST-2019-0046CC86","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.smim.2013.12.004","article-title":"Inhibition of IL-6 family cytokines by SOCS3","volume":"26","year":"2014","journal-title":"Semin. Immunol."},{"key":"2021111915542046700_BST-2019-0046CC87","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1038\/ni931","article-title":"SOCS3 negatively regulates IL-6 signaling in vivo","volume":"4","year":"2003","journal-title":"Nat. Immunol."},{"key":"2021111915542046700_BST-2019-0046CC88","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1038\/43219","article-title":"Structure and function of a new STAT-induced STAT inhibitor","volume":"387","year":"1997","journal-title":"Nature"},{"key":"2021111915542046700_BST-2019-0046CC89","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.molcel.2006.03.024","article-title":"The structure of SOCS3 reveals the basis of the extended SH2 domain function and identifies an unstructured insertion that regulates stability","volume":"22","year":"2006","journal-title":"Mol. Cell"},{"key":"2021111915542046700_BST-2019-0046CC90","doi-asserted-by":"publisher","first-page":"S223","DOI":"10.1067\/mai.2002.129945","article-title":"Update on current concepts of the molecular basis of beta2-adrenergic receptor signaling","volume":"110","year":"2002","journal-title":"J. Allergy Clin. Immunol."},{"key":"2021111915542046700_BST-2019-0046CC91","doi-asserted-by":"publisher","first-page":"S184","DOI":"10.1038\/sj.bjp.0707674","article-title":"The A(2A)-adenosine receptor: a GPCR with unique features?","volume":"153","year":"2008","journal-title":"Br. J. Pharmacol."},{"key":"2021111915542046700_BST-2019-0046CC92","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1146\/annurev.pharmtox.41.1.661","article-title":"Prostanoid receptors: subtypes and signaling","volume":"41","year":"2001","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"2021111915542046700_BST-2019-0046CC93","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.pharmthera.2004.06.003","article-title":"Pharmacology and signaling of prostaglandin receptors: multiple roles in inflammation and immune modulation","volume":"103","year":"2004","journal-title":"Pharmacol. Ther."},{"key":"2021111915542046700_BST-2019-0046CC94","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1038\/aps.2011.200","article-title":"Role of G protein-coupled receptors in inflammation","volume":"33","year":"2012","journal-title":"Acta Pharmacol. Sin."},{"key":"2021111915542046700_BST-2019-0046CC95","doi-asserted-by":"publisher","first-page":"942","DOI":"10.4161\/psb.4.10.9530","article-title":"Signaling through G protein coupled receptors","volume":"4","year":"2009","journal-title":"Plant Signal. Behav."},{"key":"2021111915542046700_BST-2019-0046CC96","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.ejphar.2015.05.016","article-title":"Structural mechanism of G protein activation by G protein-coupled receptor","volume":"763","year":"2015","journal-title":"Eur. J. Pharmacol."},{"key":"2021111915542046700_BST-2019-0046CC97","doi-asserted-by":"publisher","first-page":"7599","DOI":"10.1074\/jbc.274.12.7599","article-title":"Structure, mechanism, and regulation of mammalian adenylyl cyclase","volume":"274","year":"1999","journal-title":"J. Biol. Chem."},{"key":"2021111915542046700_BST-2019-0046CC98","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1128\/MCB.25.1.136-146.2005","article-title":"Cyclic AMP potentiates vascular endothelial cadherin-mediated cell-cell contact to enhance endothelial barrier function through an Epac-Rap1 signaling pathway","volume":"25","year":"2005","journal-title":"Mol. Cell. Biol."},{"key":"2021111915542046700_BST-2019-0046CC99","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1042\/BST20130253","article-title":"cAMP signalling in the vasculature: the role of Epac (exchange protein directly activated by cAMP)","volume":"42","year":"2014","journal-title":"Biochem. Soc. Trans."},{"key":"2021111915542046700_BST-2019-0046CC100","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1016\/j.cellsig.2009.07.009","article-title":"Selective inhibition of cytokine-activated extracellular signal-regulated kinase by cyclic AMP via Epac1-dependent induction of suppressor of cytokine signalling-3","volume":"21","year":"2009","journal-title":"Cell. Signal."},{"key":"2021111915542046700_BST-2019-0046CC101","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.bbamcr.2018.11.004","article-title":"The novel exchange protein activated by cyclic AMP 1 (EPAC1) agonist, I942, regulates inflammatory gene expression in human umbilical vascular endothelial cells (HUVECs)","volume":"1866","year":"2019","journal-title":"Biochim. Biophys. Acta Mol. Cell Res."},{"key":"2021111915542046700_BST-2019-0046CC102","doi-asserted-by":"publisher","first-page":"12058","DOI":"10.1074\/jbc.M115.642983","article-title":"Protein kinase A (PKA) phosphorylation of Shp2 protein inhibits its phosphatase activity and modulates ligand specificity","volume":"290","year":"2015","journal-title":"J. Biol. Chem."},{"key":"2021111915542046700_BST-2019-0046CC103","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1042\/BJ20071572","article-title":"Prostaglandin E1 inhibits IL-6-induced MCP-1 expression by interfering specifically in IL-6-dependent ERK1\/2, but not STAT3, activation","volume":"412","year":"2008","journal-title":"Biochem. J."},{"key":"2021111915542046700_BST-2019-0046CC104","doi-asserted-by":"publisher","first-page":"343","DOI":"10.7326\/0003-4819-115-5-343","article-title":"Survival in patients with primary pulmonary hypertension. Results from a national prospective registry","volume":"115","year":"1991","journal-title":"Ann. Intern. Med."},{"key":"2021111915542046700_BST-2019-0046CC105","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1016\/S0735-1097(03)00463-7","article-title":"Beraprost therapy for pulmonary arterial hypertension","volume":"41","year":"2003","journal-title":"J. Am. Coll. Cardiol."},{"key":"2021111915542046700_BST-2019-0046CC106","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1164\/ajrccm.165.6.2106079","article-title":"Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial","volume":"165","year":"2002","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"2021111915542046700_BST-2019-0046CC107","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1038\/263663a0","article-title":"An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation","volume":"263","year":"1976","journal-title":"Nature"},{"key":"2021111915542046700_BST-2019-0046CC108","doi-asserted-by":"publisher","first-page":"H511","DOI":"10.1152\/ajpheart.1992.262.2.H511","article-title":"Role of cAMP-dependent protein kinase in cAMP-mediated vasodilation","volume":"262","year":"1992","journal-title":"Am. J. Physiol."},{"key":"2021111915542046700_BST-2019-0046CC109","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1046\/j.1471-4159.1999.02009.x","article-title":"Interleukin-6 activates signal transducer and activator of transcription and mitogen-activated protein kinase signal transduction pathways and induces de novo protein synthesis in human neuronal cells","volume":"73","year":"1999","journal-title":"J. Neurochem."},{"key":"2021111915542046700_BST-2019-0046CC110","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1038\/sj.embor.embor802","article-title":"Phosphorylation of the Stat1 transactivating domain is required for the response to type I interferons","volume":"4","year":"2003","journal-title":"EMBO Rep."},{"key":"2021111915542046700_BST-2019-0046CC111","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2019.01.003","article-title":"Tocilizumab in giant cell arteritis. observational, open-label multicenter study of 134 patients in clinical practice","year":"2019","journal-title":"Semin. Arthritis Rheum."},{"key":"2021111915542046700_BST-2019-0046CC112","first-page":"211","article-title":"Anti-interleukin-6 therapy in rheumatoid arthritis","volume":"68","year":"2010","journal-title":"Bull. NYU Hosp. Jt Dis."},{"key":"2021111915542046700_BST-2019-0046CC113","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1016\/j.intimp.2005.05.010","article-title":"Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family","volume":"5","year":"2005","journal-title":"Int. Immunopharmacol."},{"key":"2021111915542046700_BST-2019-0046CC114","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1007\/s00380-009-1215-5","article-title":"The efficacy of tocilizumab in a patient with pulmonary arterial hypertension associated with Castleman's disease","volume":"25","year":"2010","journal-title":"Heart and vessels"},{"key":"2021111915542046700_BST-2019-0046CC115","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1111\/apt.14449","article-title":"Systematic review with network meta-analysis: comparative assessment of tofacitinib and biological therapies for moderate-to-severe ulcerative colitis","volume":"47","year":"2018","journal-title":"Aliment. Pharmacol. Ther."},{"key":"2021111915542046700_BST-2019-0046CC116","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1080\/1744666X.2018.1532291","article-title":"Tofacitinib for the treatment of ulcerative colitis","volume":"14","year":"2018","journal-title":"Expert Rev. Clin. Immunol."},{"key":"2021111915542046700_BST-2019-0046CC117","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1007\/s40265-017-0829-7","article-title":"Tocilizumab: a review in rheumatoid arthritis","volume":"77","year":"2017","journal-title":"Drugs"},{"key":"2021111915542046700_BST-2019-0046CC118","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/S1074-7613(04)00022-6","article-title":"SOCS3 is a critical physiological negative regulator of G-CSF signaling and emergency granulopoiesis","volume":"20","year":"2004","journal-title":"Immunity"},{"key":"2021111915542046700_BST-2019-0046CC119","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1172\/JCI25660","article-title":"SOCS-3 negatively regulates innate and adaptive immune mechanisms in acute IL-1-dependent inflammatory arthritis","volume":"116","year":"2006","journal-title":"J. Clin. Invest."},{"key":"2021111915542046700_BST-2019-0046CC120","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1038\/icb.2011.29","article-title":"IL-6 promotes acute and chronic inflammatory disease in the absence of SOCS3","volume":"90","year":"2012","journal-title":"Immunol. Cell Biol."},{"key":"2021111915542046700_BST-2019-0046CC121","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1038\/nm763","article-title":"Reciprocal regulation of gastrointestinal homeostasis by SHP2 and STAT-mediated trefoil gene activation in gp130 mutant mice","volume":"8","year":"2002","journal-title":"Nat. Med."},{"key":"2021111915542046700_BST-2019-0046CC122","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1006\/meth.1998.0593","article-title":"Inducible gene targeting in mice using the Cre\/lox system","volume":"14","year":"1998","journal-title":"Methods"}],"container-title":["Biochemical Society Transactions"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/portlandpress.com\/biochemsoctrans\/article-pdf\/47\/4\/1143\/850911\/bst-2019-0046c.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/portlandpress.com\/biochemsoctrans\/article-pdf\/47\/4\/1143\/850911\/bst-2019-0046c.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,21]],"date-time":"2024-07-21T09:13:51Z","timestamp":1721553231000},"score":1,"resource":{"primary":{"URL":"https:\/\/portlandpress.com\/biochemsoctrans\/article\/47\/4\/1143\/219682\/Is-there-a-role-for-prostanoid-mediated-inhibition"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,24]]},"references-count":122,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2019,7,24]]},"published-print":{"date-parts":[[2019,8,30]]}},"URL":"https:\/\/doi.org\/10.1042\/bst20190046","relation":{},"ISSN":["0300-5127","1470-8752"],"issn-type":[{"value":"0300-5127","type":"print"},{"value":"1470-8752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,24]]}}}